Small Molecule for Diabetic Macular Edema and Wet AMD
Potential small molecule pharmacologic treatment for retinal neovascular disease
The proprietary technology modulates endogenous factors released during the inflammatory process at the early pathogenic stages of age-related macular degeneration (AMD), diabetic macular edema (DME) and other retinal neovascular conditions. Approximately 142 million people are affected by AMD (all forms), and about 105 million people are affected by diabetic eye disease worldwide (1). These two diseases alone are two of the leading causes of blindness worldwide.
In an early in-vivo preclinical study, the lead drug candidate demonstrated the ability to inhibit vascular endothelial growth factor (VEGF) induced vascular leakage comparable to anti-VEGF therapy, and without loss of native microvasculature. Vessels appeared to be better preserved than with the anti-VEGF treatment suggesting less occlusion.
In addition to its early intervention in the neovascular disease cascade, we intend to evaluate the potential of these proprietary molecules to be dosed less frequently and exert therapeutic effects over a longer period of time than current anti-VEGF biologic drugs used as standard of care.
(1) Market Scope, The Global Retinal Pharmaceuticals & Biologic Market, 2015.